Diwakar Davar, M.D.October 19, 2023

FDA 483 - Diwakar Davar, M.D. - October 19, 2023

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Diwakar Davar, M.D.

Record Details

Diwakar Davar, M.D., a Sponsor-Investigator in Pittsburgh, PA, was cited for significant deficiencies related to Institutional Review Board (IRB) oversight during clinical studies. The inspection revealed that research activities continued during a lapse in IRB approval and that changes to a study protocol were implemented without prior IRB approval. These findings indicate a failure to ensure proper ethical and regulatory review of clinical research.

Company: Diwakar Davar, M.D.
Inspection Date: October 19, 2023
Product Type: Drugs
Office: Philadelphia District Office
Person: Cynthia L. Rakestraw

Open in Dashboard

ID · a4b080ec-fb6d-49c5-8b55-676890677bd0